Related Experiment Video

Updated: Aug 25, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Anti-epileptic therapy and behaviour disturbances in children

S Domizio1, A Verrotti, L A Ramenghi

  • 1Department of Neonatology, University of Chieti, Ospedale Pediatrico, Italy.

Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|August 1, 1993
PubMed

Insights

Phenobarbital and other anti-epileptic drugs can cause behavioral issues in children. This study found hyperactivity and irritability were common side effects in children treated with these medications.

Area of Science:

  • Pediatric Neurology
  • Child Psychology
  • Pharmacology

Background:

  • Anti-epileptic drugs (AEDs) are crucial for managing epilepsy in children.
  • Behavioral side effects of AEDs can impact a child's quality of life and treatment adherence.
  • Phenobarbital is a commonly prescribed AED with a known, though not fully characterized, side effect profile.

Purpose of the Study:

  • To investigate and compare the behavioral effects of phenobarbital versus other AEDs in a pediatric population.
  • To identify the prevalence and types of behavioral disturbances associated with phenobarbital treatment.
  • To assess the significance of behavioral changes in children receiving different AED regimens.

Main Methods:

  • A cohort of 300 children (aged 3.1 months to 15.9 years) treated with AEDs was studied.
  • Children were divided into two groups: Group A (n=197) on phenobarbital, and Group B (n=103) on other AEDs.
  • Parents completed a 7-item questionnaire assessing hyperactivity, irritability, sleep disturbances, and drowsiness.

Main Results:

  • A significantly higher proportion of children on phenobarbital (76.1%) exhibited behavioral disturbances compared to those on other AEDs (31%) (P < 0.0001).
  • Hyperactivity was the most frequently reported behavioral issue across both groups.
  • Sleep disturbances and drowsiness were also noted as common adverse effects.

Conclusions:

  • Phenobarbital is associated with a substantially higher risk of behavioral disturbances in children compared to other AEDs.
  • Healthcare providers should carefully monitor for and manage behavioral side effects in pediatric patients prescribed phenobarbital.
  • Further research is warranted to elucidate the mechanisms underlying AED-induced behavioral changes and to develop targeted interventions.

More Related Videos

Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...